Evidence map›Paper›PMID 41583364›Full record

ArticleEClinicalMedicine2026

Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study.

Aleksander M Bogdanski, Derk C F Klatte, Bert A Bonsing, Lodewijk A A Brosens, Evelien Dekker, Lydia G van der Geest, Joep E G Ijspeert, Jan J Koornstra, Mariëtte C A van Kouwen, Alexandra M J Langers and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Aleksander M BogdanskiDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
Derk C F KlatteDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
Bert A BonsingDepartment of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Lodewijk A A BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Evelien DekkerDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Lydia G van der GeestDepartment of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
Joep E G IjspeertDepartment of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jan J KoornstraDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, the Netherlands.
Mariëtte C A van KouwenDepartment Gastroenterology and Hepatology, Radboud University Medical Centre Nijmegen, Nijmegen, the Netherlands.
Alexandra M J LangersDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
Maartje NielsenDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Dewkoemar RamsoekhDepartment of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Manon C SpaanderDepartment of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Wouter H de Vos Tot Nederveen CappelDepartment of Gastroenterology and Hepatology, Isala Zwolle, Zwolle, the Netherlands.
Jeanin E Van HooftDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
Monique E van LeerdamDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
Dutch Pancreatic Cancer Group
Collaborative investigators from the Dutch Foundation for Detection of Hereditary Tumors

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Individuals with Lynch syndrome (LS) are advised to undergo pancreatic ductal adenocarcinoma (PDAC) surveillance if their lifetime risk is ≥5%, however, evidence is limited. This study quantifies lifetime risk and survival of three cancers relevant to PDAC surveillance, including PDAC, ampullary carcinoma (AC) and distal cholangiocarcinoma (dCC), to evaluate whether surveillance is justified. Methods: This retrospective nationwide Dutch cohort study included individuals with LS pathogenic variants (PVs) in Findings: In total, 2605 individuals with LS were included (median age 63.9 years; IQR 53.7-74.0), of whom 1515 (58.2%) were female. PVs were identified in Interpretation: In LS, the combined lifetime risk of PDAC, AC and dCC ranged from 0 to 3.4% across different genes, remaining below the 5% risk threshold for PDAC surveillance. Additionally, having an affected relative did not appear to increase risk. These findings suggest that current surveillance recommendations for individuals with LS should be re-evaluated. Funding: Lynch-Polyposis.

Indexed as

Cumulative incidenceLynch syndromePancreas cancerSurveillance

Identifiers

PMID41583364
PMCPMC12828513

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.